The Goldman Sachs Future Health Care Equity ETF (GDOC) gained momentum after positive news from its largest holding, Eli Lilly (LLY), whose price target was raised by JPMorgan. GDOC has returned 11.8% over the past three months, recovering from earlier underperformance in 2026. The fund invests actively in innovative healthcare firms, focusing on genomics, precision medicine, and digital health, and benefits from potential tailwinds like future interest rate cuts and increased M&A activity. Another key holding, Johnson & Johnson, also contributed with nearly 30% returns year-to-date and recent FDA approval for a cardiac catheter. GDOC is well-positioned for growth in the second half of the year as healthcare innovation and economic improvements drive demand.
Eli Lilly has solidified its dominance in the global obesity drug market, maintaining a 60-61% market share in the US despite rising competition and pricing challenges. The company continues to grow through increasing prescriptions and expanding glob...
The Vanguard Growth ETF (VUG) charges a very low fee of 0.03%, costing about $3 annually on a $10,000 investment. However, the real risk lies in its heavy concentration, with over 65% of the fund invested in just ten large-cap stocks like NVIDIA, App...
Eli Lilly shows strong performance with 48% revenue growth driven by GLP-1 drugs Mounjaro and Zepbound, raising 2026 guidance significantly. Novo Nordisk struggles with pricing cuts and pipeline setbacks, keeping its stock range-bound despite solid s...
Eli Lilly became the first pharmaceutical company valued over $1 trillion, driven by strong revenue growth and promising drugs like retatrutide and orforglipron. The company reported a 47.67% revenue increase in Q2 and raised its 2026 revenue guidanc...
Aktis Oncology, a clinical-stage radiopharmaceutical company, closed at $25.00 on August 18, 2026, with a market cap of $1.4 billion and $517.3 million in cash, supporting operations into 2029. Its lead candidate targets Nectin-4 with trial data expe...
